Dulaglutide became the first funded GLP1 receptor agonist for the treatment of type 2 diabetes in Aotearoa, New Zealand, in September 2021. Dulaglutide is a potential game-changer in the management of diabetes as it is a potent glucose-lowering agent without causing hypoglycaemia alone and reduces cardiovascular disease and weight independently of its effect on glucose levels.
In this webinar, Ryan will cover:
- The uptake of dulaglutide in Aotearoa New Zealand.
- Update the evidence and new clinical indications for dulaglutide.
- When to use dulaglutide.
- ‘Clinical pearls’ for dulaglutide use.
Ryan Paul is an endocrinologist and diabetologist at Te Whatu Ora Waikato. He is active in research in his roles as a Senior Lecturer at the Universities of Waikato and Auckland, and as a Clinical Associate of the Maurice Wilkins Centre. He also has a key role in teaching as a member of the Royal Australasian College of Physicians (RACP) Training Committees and with Diabetes Nurse Prescribers in New Zealand, and was awarded the New Zealand Clinical Educator of the Year by the New Zealand Medical Council in 2019. Ryan is the Immediate Past President of the New Zealand Society of Endocrinology (NZSE) and an Executive Member of the New Zealand Society for the Study of Diabetes (NZSSD). He recently convened the new NZSSD national guidance on the management of type 2 diabetes.